CA2939261C - Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same - Google Patents

Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same Download PDF

Info

Publication number
CA2939261C
CA2939261C CA2939261A CA2939261A CA2939261C CA 2939261 C CA2939261 C CA 2939261C CA 2939261 A CA2939261 A CA 2939261A CA 2939261 A CA2939261 A CA 2939261A CA 2939261 C CA2939261 C CA 2939261C
Authority
CA
Canada
Prior art keywords
acid
poly
nanoparticle
therapeutic
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2939261A
Other languages
English (en)
French (fr)
Other versions
CA2939261A1 (en
Inventor
Maria Figueiredo
Erick PEEKE
David Dewitt
Christina Van Geen Hoven
Greg Troiano
James Wright
Young-Ho Song
Hong Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CA2939261A1 publication Critical patent/CA2939261A1/en
Application granted granted Critical
Publication of CA2939261C publication Critical patent/CA2939261C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
CA2939261A 2014-02-13 2015-02-13 Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same Active CA2939261C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461939363P 2014-02-13 2014-02-13
US61/939,363 2014-02-13
PCT/US2015/015887 WO2015123562A1 (en) 2014-02-13 2015-02-13 Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same

Publications (2)

Publication Number Publication Date
CA2939261A1 CA2939261A1 (en) 2015-08-20
CA2939261C true CA2939261C (en) 2023-03-28

Family

ID=52595474

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2939261A Active CA2939261C (en) 2014-02-13 2015-02-13 Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same

Country Status (11)

Country Link
US (2) US10080723B2 (OSRAM)
EP (1) EP3104838B1 (OSRAM)
JP (1) JP6573895B2 (OSRAM)
CA (1) CA2939261C (OSRAM)
DK (1) DK3104838T3 (OSRAM)
ES (1) ES2770733T3 (OSRAM)
HU (1) HUE047934T2 (OSRAM)
PL (1) PL3104838T3 (OSRAM)
PT (1) PT3104838T (OSRAM)
SI (1) SI3104838T1 (OSRAM)
WO (1) WO2015123562A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3104838T (pt) 2014-02-13 2020-02-14 Pfizer Nanopartículas terapêuticas que compreendem um agente terapêutico e métodos de fazer e utilizar as mesmas
EP4299058A3 (en) 2014-06-24 2024-03-27 The Trustees of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
US20170049709A1 (en) 2015-08-21 2017-02-23 Pfizer Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
JP2019509299A (ja) * 2016-03-22 2019-04-04 ファイザー・インク 治療用ナノ粒子を調製する方法
CA3060306A1 (en) 2017-05-09 2018-11-15 Dignity Health Drug delivery composition and method of fabrication
WO2019055539A1 (en) 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
US12357582B2 (en) 2017-11-03 2025-07-15 The Trustees Of Princeton University Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations
EP3784705A4 (en) * 2018-04-23 2022-03-02 Graybug Vision, Inc. IMPROVED CONTINUOUS PRODUCTION OF MICROPARTICLES
CN120305263A (zh) 2018-06-15 2025-07-15 汉达癌症医药责任有限公司 卡博替尼的盐类于制备治疗癌症的剂型的用途
WO2020018890A1 (en) 2018-07-19 2020-01-23 Prudhomme Robert K Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
WO2024108094A1 (en) * 2022-11-18 2024-05-23 Haima Therapeutics, Llc Lyophilization buffers for peptide-decorated liposomes
AU2024215796A1 (en) 2023-01-31 2025-05-15 Handa Oncology, Llc Improved cabozantinib compositions and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6869884B2 (en) * 2002-08-22 2005-03-22 Chartered Semiconductor Manufacturing Ltd. Process to reduce substrate effects by forming channels under inductor devices and around analog blocks
AU2004259209A1 (en) * 2003-07-23 2005-02-03 Pr Pharmaceuticals, Inc. Controlled release compositions
EA020954B1 (ru) 2008-06-16 2015-03-31 Бинд Терапьютикс, Инк. Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака
AU2013315125B2 (en) 2012-09-17 2018-07-26 Pfizer Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
EP2895156B1 (en) 2012-09-17 2019-05-08 Pfizer Inc. Process for preparing therapeutic nanoparticles
PE20160930A1 (es) * 2013-09-16 2016-09-03 Astrazeneca Ab Nanoparticulas polimericas terapeuticas y metodos para su elaboracion y uso.
PT3104838T (pt) 2014-02-13 2020-02-14 Pfizer Nanopartículas terapêuticas que compreendem um agente terapêutico e métodos de fazer e utilizar as mesmas
ES2834927T3 (es) * 2014-03-14 2021-06-21 Pfizer Nanopartículas terapéuticas que comprenden un agente terapéutico y procedimientos de fabricación y uso de las mismas

Also Published As

Publication number Publication date
DK3104838T3 (da) 2020-02-24
JP6573895B2 (ja) 2019-09-11
US20190111004A1 (en) 2019-04-18
US10583092B2 (en) 2020-03-10
ES2770733T3 (es) 2020-07-02
JP2017505800A (ja) 2017-02-23
EP3104838B1 (en) 2020-01-01
HUE047934T2 (hu) 2020-05-28
WO2015123562A1 (en) 2015-08-20
US20170042828A1 (en) 2017-02-16
US10080723B2 (en) 2018-09-25
CA2939261A1 (en) 2015-08-20
SI3104838T1 (sl) 2020-04-30
PT3104838T (pt) 2020-02-14
PL3104838T3 (pl) 2020-07-13
EP3104838A1 (en) 2016-12-21

Similar Documents

Publication Publication Date Title
US10583092B2 (en) Therapeutic nanoparticles comprising a protonatable nitrogen therapeutic agent and methods of making and using same
US20170119672A1 (en) Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods Of Making And Using Same
US10577351B2 (en) Therapeutic polymeric nanoparticles and methods of making and using same
KR20170023173A (ko) 표적화된 치료 나노입자 및 그의 제조 및 사용 방법
US20180311177A1 (en) Therapeutic Nanoparticles Comprising A Therapeutic Agent and Methods of Making and Using Same
US10022360B2 (en) Polymeric nanoparticles and methods of making and using same
HK1254347B (en) Therapeutic polymeric nanoparticles and methods of making and using same
NZ717615B2 (en) Therapeutic polymeric nanoparticles and methods of making and using same

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200211

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251001

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260113

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260205